iuvo BioScience Hires Industry Executive to Lead Laboratory Business

Rochester, NY, January 31, 2023 – iuvo BioScience, a specialty CRO providing laboratory services, preclinical and clinical development services, and scientific consulting services to biopharmaceutical- and medical device customers, today announced it has hired David Kudla, MBA, as Vice President, Laboratory Operations.  This hire demonstrates iuvo’s continued commitment to operational excellence, client service and investment in the business to support the company’s growth trajectory.

David is a well-established senior operational and business leader who brings decades of experience in operational, quality and general management assignments.  David spent nearly twenty years at Celltech Pharmaceuticals in various quality roles prior to moving to Advancis Pharmaceutical Corporation where he served as the VP of Quality Assurance.  David then moved to Shire in a senior quality assurance and quality control role prior to joining Unither in 2011 where he ultimately served as the General Manager of their North American operation.  Just prior to joining iuvo, David was with ECRI serving as Director in their Strategy and Enterprise Project Management Office delivering enterprise strategy deployment and operational excellence.

David is excited about the opportunity, stating “The vision and future potential for iuvo is compelling – they are poised for significant growth and recognize the strength of their business model is in their highly responsive, highly consultative, highly flexible approach to customer service.  I’m excited to be part of this next phase of iuvo.”

Daniel Spasic, Board Chair of iuvo BioScience, offered his welcome as well: “David will be an important contributor to the business as a senior professional with a unique combined background in operations, QA and QC. His expertise will benefit our broad array of customers as well as our team in Laboratory Operations.  I am excited to work with David and look forward to the impact of his leadership on the business and client service.”

Ben Burton, CEO of iuvo BioScience, provided these final comments: “David is a great cultural fit and absolutely the right person at the right time for iuvo.  I look forward to having him on our Executive Committee and charting a path of growth and customer service that embodies our PROTM (Partner Research Organization) model.”

About iuvo BioScience

Headquartered in Rochester, NY, iuvo BioScience is a highly specialized provider of preclinical, clinical, and consulting services to biotech and medical device customers. The company’s facility features laboratories for analytical chemistry, microbiology, pharmacology, and toxicology, as well as an on-site AAALAC-accredited vivarium to support preclinical testing. Through the company’s Oculos Clinical Research subsidiary, iuvo provides a suite of clinical trial services including clinical trial design, regulatory, biometrics, pharmacovigilance, project and site management. Under the Lumino Advisors brand, the company also has an end-to-end scientific consulting offering spanning from regulatory strategy, dossier development, preclinical and CMC consulting and strategic planning through trial execution and regulatory submission. Additional information about iuvo is available at www.iuvobioscience.com.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm with more than $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. For additional information, visit www.ampersandcapital.com or follow us on LinkedIn.